Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Ovarian Cancer

“At our institution, we give radiation to these patients, which differs from what we saw in RUBY, where radiation was not given. Interestingly enough, none of these patients at time of analysis had disease progression or recurrence.”

Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center, discusses the safety and efficacy of dostarlimab-gxly (Jemperli) plus chemotherapy in patients with advanced endometrial cancer according to findings from a real-world, retrospective, single-institution analysis.